US2019218508A1PendingUtilityA1
Methods of cell separation
Est. expiryApr 15, 2033(~6.8 yrs left)· nominal 20-yr term from priority
Inventors:Jeffrey Drew
C12N 2500/62C12N 5/0641C12N 2500/34C12N 5/0087C12N 2500/32C12N 5/0634A01N 1/0221A01N 1/125
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to the use of a combination of: (i) a macromolecular erythrocyte sedimentation enhancer, and (ii) dimethyl sulphoxide (DMSO), dimethylglycine (DMG) and/or valine; to recover non-erythrocyte blood cells from a blood cell-containing sample and/or to prime non-erythrocyte blood cells to protect their integrity in subsequent cryopreservation step(s).
Claims
exact text as granted — not AI-modified1 . A method for priming non-erythrocyte blood cells for cryopreservation, said method comprising contacting the cells with DMSO, DMG and/or valine, wherein when the cells are contacted with the DMSO, DMG and/or valine, the concentration of DMSO, DMG and/or valine does not exceed 5% v/v.
2 . A method according to claim 1 , wherein the non-erythrocyte blood cells are present in the form of a non-erythrocyte blood cell fraction that has already undergone a treatment(s) to remove erythrocytes.
3 . A method according to claim 1 , wherein the non-erythrocyte blood cells are present in the form of a blood cell-containing sample which comprises said non-erythrocyte blood cells.
4 . A method according to claim 3 , wherein the sample is whole blood.
5 . A method according to claim 1 , wherein the non-erythrocyte blood cells comprise white blood cells.
6 . A method according to claim 1 , wherein the method is for increasing the proportion of viable white blood cells recovered following a subsequent cryopreservation.
7 . A method according to claim 1 , wherein the non-erythrocyte blood cells are taken from a mammal.
8 . A method according to claim 1 , wherein the non-erythrocyte blood cells are taken from a human.
9 . A method according to claim 1 , which comprises contacting the non-erythrocyte blood cells with a combination of:
(i) a macromolecular erythrocyte sedimentation enhancer, and (ii) the DMSO, DMG and/or valine; wherein when the blood cell-containing sample is contacted with components (i) and (ii), the concentration of component (ii) does not exceed 5% v/v.
10 . A method for priming a non-erythrocyte blood cell fraction for cryopreservation, said method comprising contacting the cell fraction with a combination of:
(i) a macromolecular erythrocyte sedimentation enhancer, and (ii) DMSO, DMG and/or valine; wherein when the blood cell-containing sample is contacted with components (i) and (ii), the concentration of component (ii) does not exceed 5% v/v.
11 . A method according to claim 10 , comprising contacting the cell fraction with a composition comprising components (i) and (ii), wherein the cell fraction and the composition are mixed at a ratio of 10:1 to 1:10, preferably 5:1 to 1:5, more preferably 2:1 to 1:2.
12 . A method according to claim 9 , comprising contacting the non-erythrocyte blood cells with a composition comprising components (i) and (ii), wherein the composition comprises 0.1-10% w/v of component (i) and 0.1-10% v/v of component (ii).
13 . A method according to claim 9 , wherein, once the non-erythrocyte blood cells have been contacted with components (i) and (ii), the concentration of component (i) is 0.25 to 5% w/v, and the concentration of component (ii) is 0.25 to 5% v/v.
14 . A method according to claim 9 , wherein component (i) is dextran and component (ii) is DMSO.
15 . A method according to claim 9 , wherein component (i) is dextran having a molecular weight of at least 50 kDa.
16 . A method according to claim 9 , wherein component (i) is dextran 500 and component (ii) is DMSO.
17 . A method for preparing non-erythrocyte blood cells for cryopreservation, which method comprises (a) a method as defined in claim 1 , and (b) adding a cryoprotectant to the thus obtained non-erythrocyte blood cells.
18 . A method for the cryopreservation of non-erythrocyte blood cells, which method comprises (a) a method as defined in claim 1 , (b) adding a cryoprotectant to the thus obtained non-erythrocyte blood cells, and (c) cryopreserving the non-erythrocyte blood cells.
19 . A method for the cryopreservation and subsequent recovery of non-erythrocyte blood cells, which method comprises (a) a method as defined in claim 1 , (b) adding a cryoprotectant to the thus obtained non-erythrocyte blood cells, (c) cryopreserving the non-erythrocyte blood cells, and (d) thawing the non-erythrocyte blood cells.
20 . A method according to claim 17 , wherein the cryoprotectant comprises DMSO.
21 . A composition comprising (i) a macromolecular erythrocyte sedimentation enhancer, and (ii) DMSO, DMG and/or valine, which composition is suitable for use in recovering non-erythrocyte blood cells from a blood cell-containing sample and/or priming non-erythrocyte blood cells to protect their integrity in subsequent cryopreservation and thawing steps, wherein if component (ii) is DMSO, then the concentration of DMSO in the composition is 10% v/v or less.
22 . A composition according to claim 21 , wherein component (i) is dextran and component (ii) is DMSO.
23 . A composition according to claim 21 , wherein component (i) is dextran having a molecular weight of at least 50 kDa.
24 . A composition according to claim 21 , wherein component (i) is dextran 500 and component (ii) is DMSO.
25 . A composition according to claim 21 , wherein the concentration of component (i) is 1-5% w/v and the concentration of component (ii) is 1-5% v/v.
26 . An apparatus comprising a composition as defined in claim 21 , which apparatus is a bottle, a blood bag, a pre-filled syringe for injection into a blood bag, or a kit comprising a composition as defined in claim 21 and a blood collection vessel.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.